Short Term Portfolio

JANX
- Stock crashed from overreaction from phase 1 data readout
- Entered bit too early but still attractive entry point mid-long term
- Averaged down heavily from the entry price of $17 (average down to 14.46 by Jan 13)

BHVN - Oversold and dilution done. Insider buys exceeding $25M, R&D cut decision to focus on core pipelines. There are 2 upcoming catalysts this quarter. - Mid-long term hold candidate

MLTX
- Was on watchlist and bought with the update on FDA Type B meeting|
- Delay with the news that was anticipated mid December provided another attractive opportunity

NTLA (Closed to secure cash reserve for volatile Thanksgiving - Christmas period)
- Oversold and overreaction from clinical stage clinical paused due to Grade 4 liver issue. Risk-benefit factor is strong with data supporting it. Affected participant unfortunately passed away and is said to be over 80 y.o.
- Mid-long term hold candidate

INAB (Closed with good profit, SNO announcement was not released via PR but through corporate presentation update, stock to watch for the future)
- Nano cap with low float, hoping for a positive reaction with updates on phase 1 and 2 studies (INB-200 & INB-400) during Society for Neuro-Oncology (SNO) Annual Meeting between 19-22 Nov.
- Compelling data showing potential, but financial situation is dire.
- Small position, might hold for a long-term

KURA (Closed to add shares on NTLA & BHVN, regretting not to close when it hit over $12 on 14th Nov)
- Opened position with FDA approval
- Product launch ready
- Significant milestone payment due, patient convenience is superior, upcoming catalysts

SGMO (Closed to add shares on long-term investment portfolio)
- This is little more risky play, short on cash
- Fabry asset shows promise and needs a strategic partnership for commercialization, good news can shift the direction. Science is strong, but very poor execution from the management.

MLTX (Took a quick profit again, thesis stands strong, great hold for mid-long term)
- Extremely strong potential
- Cash position is strong
- Series of upcoming catalysts

OSTX (Sold at slight loss)
- 2nd Entry
- FDA Type C meeting scheduled for December.
- Pritority Review Voucher play might be still in game
- Cash runway is concern

XLO (Exceptionally promising data failed to attract investors)
- Exceptional potential, big interests from big pharmas
- Funding is sufficient into 2027, however dilution is big concern
- Clinical trials early stage, 1/2, and preclinical
- Validation of efficacy will be essential
- Few near term catalysts on 7th November with additional data expected
- Long term investment potential

CADL (Conference failed to gain much attention due to market volatility)
- Great cash runway (over 3 years)
- Promising MoA and oncology efficacy
- Conference presentations on 7th November

ABEO (Closed with loss on 6/Nov)
- Commercialisation ready
- Undervalued for the potential of its approved pipeline
- May consider moving to long term portfolio

IMMX (Stop Loss hit on 5/Nov)
- Promising data
- Conference presentation on early December
- Will consider re-entry in the future

IMRN (Exit on 31/Oct due to delay in phase 2 top line results, apparently due to the shut down)
- Earnings mid October
- Phase 2 results for their main product Travelan is anticipated in October with EOP2 meeting with FDA planned after the read out
- Cash is concern, and I plan to exit with a news.

PEPG (Exit on 27/Oct at $5.40 pre-market)
- Promising DM1 data
- 3-6 months hold for now, may move to long term portfolio later
- Exited with a small gain affected by Avidity's acquisition

OMER (Exit on 20/Oct at $8.05 at loss)
- Added with NVO's licensing news on 15th of October,2025
- Phase 3 asset out-licensing with good upfront fee, milestones and tiered royalties up to $2.1B.
- PDUFA also coming at the end of the year
- May add little more if the price falls below $8, may consider holding through next year
- Exited due to loss of momentum

DYN (Exit on 20/Oct at $17.06)
- Phase 1/2 for DMD is expected before the end of the year, anticipation run expected
- Cash runway good into 2027 with recent dilution
- Good candidate for both short & long term, RNA is challenging DM1 pipeline with more advanced regulatory progress, but DYN has edge with multiple pipelines and can be considered undervalued at the moment.
- Target hit

SLS (Exit on 17/Oct at $2.38 after market spike)
- Presentation for progress on highly anticipated Phase 3 REGAL is planned on 29th October
- Phase 3 data to be expected before the EOY.

KYTX (Exit on 8/Oct at $7.6)
- October 29 Catalyst for KYV-101 on Myasthenia gravis Phase 2 Interim Data
- Another Phase 1 additional data to be expected in H2 2025
- Phase 2 for Stiff-person syndrome is expected in first half of 2026, if the result are good BLA is planned for late 2026
- Cash runway good into Q1 2027
- Great potential for long term as well

OSTX (Exit on 10/Oct at $2.38 with a spike)
- 10th of October and 13th of October, data release and presentation
- BLA planned
- Cash is concern, short-term swing idea.

MLTX (I exited between $7.40~$8.30 Final Exit on 7/Oct)
- Oversold due to recent near miss Phase 3 trial
- Market cap near cash level
- Strong potential for rebound with upcoming catalysts
- Candidate for both short & long term